Companies › Newleos Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Psychiatry; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NTX-1472 V1a receptor antagonist | AVPR1A | Phase 2 | Social Anxiety Disorder (SAD) | Jan 2027 |
| NTX-2001 TAAR1 receptor partial agonist | TAAR1 | Phase 1 | Alcohol Use Disorder | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07323784 | NTX-1472 | Phase 2 | Social Anxiety Disorder (SAD) | Psychiatry | Jan 2027 |
| NCT07520292 | NTX-2001 | Phase 1 | Alcohol Use Disorder | Psychiatry | Mar 2027 |
Draig Therapeutics Kadence Bio HB BioTech Beckley Psytech Synendos Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.